Arcturus Therapeutics Holdings Inc. — Form 8-K Summary
Reporting date: November 1, 2022. The filing reports entry into a material collaboration and license agreement; it does not provide quarterly financial statements or a defined financial reporting period.
Business Context and Transaction
Arcturus entered into a Collaboration and License Agreement with CSL Seqirus, a CSL Limited company and influenza vaccine provider, covering the research, development, manufacture and global commercialization of self-amplifying mRNA vaccines.
- Licensed technologies include Arcturus’s STARR mRNA technology, LUNAR lipid-mediated delivery technology, and related manufacturing expertise.
- CSL Seqirus receives exclusive global access for vaccines targeting SARS-CoV-2, influenza and three other globally prevalent respiratory infectious diseases.
- CSL Seqirus receives global non-exclusive access to Arcturus’s pandemic-preparedness intellectual property, with a right to convert that access to an exclusive license.
Financial Terms and Key Metrics
| Item | Reported terms |
|---|---|
| Up-front payment | $200 million |
| Development milestones | Potentially more than $1.3 billion if products are registered in the licensed fields |
| Commercial milestones | Potentially up to $3 billion based on net sales of vaccines |
| COVID-19 economics | Arcturus is entitled to a 40% share of net profits from COVID-19 vaccine sales |
| Other vaccine royalties | Up to low-double-digit royalties on annual net sales for influenza and three other specified pathogens, plus royalties on pandemic-preparedness vaccine revenues |
The filing does not state the timing of payment recognition, accounting treatment, expected cash-flow impact, margins, debt, liquidity, or actual revenue and profit effects. All contingent payments are subject to conditions, requirements, royalty reductions and other limitations in the agreement.
Responsibilities and Material Terms
- Arcturus will lead certain U.S. and European regulatory activities for ARCT-154 and research and development for a next-generation COVID-19 vaccine candidate.
- CSL Seqirus will lead and be responsible for other research and development activities across COVID-19, influenza and the additional fields.
- Arcturus will provide CSL Seqirus with a five-year credit against milestone payments to offset certain requested non-COVID-19 research and development expenses.
- CSL Seqirus will have the sole exclusive right to commercialize products developed under the collaboration.
- The agreement supports Arcturus’s obligations under its BARDA award for rapid pandemic influenza response announced in August 2022.
Conditions, Outlook and Risks
- The agreement becomes effective only after expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
- Either party may terminate for material breach after notice and an opportunity to cure.
- CSL Seqirus may terminate the agreement entirely or by field for convenience, subject to restrictions before the first commercial sale of a vaccine product in specified markets, including restrictions applicable to the influenza field.
- CSL Seqirus may also terminate for safety concerns, clinical-data nonviability, commercial nonviability and other specified reasons.
- Potential milestone, profit-share and royalty payments depend on successful development, regulatory registration, commercialization, sales and compliance with contractual conditions.
Management did not provide quantitative guidance or a broader financial outlook in the filing. The filing states that its description is only a partial summary and that the complete agreement will be filed in a subsequent periodic report.
Most Important Facts to Verify
- Whether the Hart-Scott-Rodino waiting period expired and when the agreement became effective.
- The timing and accounting treatment of the $200 million up-front payment.
- The complete milestone, royalty, profit-sharing, expense-credit and royalty-reduction provisions in the definitive agreement.
- Development and regulatory progress for ARCT-154 and the next-generation COVID-19 vaccine candidate.
- Any termination rights exercised, clinical or commercial setbacks, and the effect of such events on contingent consideration.
- Recognition of collaboration revenue, cash balances, liquidity and other financial effects in subsequent periodic filings.